SCHEMBL6713974

SCHEMBL6713974

O=C(O)Cc1ccccc1-c1noc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.49
ESR2 Q92731 5/20 0.49
FFAR4 Q5NUL3 1/20 0.48
AKR1B1 P15121 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
HIF1A Q16665 1/20 0.42
MAPT P10636 1/20 0.41
KDM4E B2RXH2 2/20 0.40
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 3/20 0.39
LMNA P02545 3/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA3 P07451 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6711049 0.82 ESR1 (0.56) ESR1ESR2FFAR4HIF1ALMNA
SCHEMBL27439734 0.81 PKM (0.50) ESR1ESR2FFAR4TDP1ALDH1A1
Methane SCHEMBL27462098 0.81 ESR1 (0.54) ESR1ESR2FFAR4HIF1ALMNA
SCHEMBL933225 0.78 ESR1 (0.50) ESR1ESR2FFAR4LMNACA12
SCHEMBL2478804 0.77 ESR1 (0.46) ESR1ESR2FFAR4ALDH1A1GAA
SCHEMBL6711210 0.76 ESR1 (0.49) ESR1ESR2FFAR4HIF1ARAB9A
Hydrochloric Acid SCHEMBL6710060 0.76 ESR1 (0.49) ESR1ESR2FFAR4LMNACA12
SCHEMBL75124 0.76 MAPT (0.62) ALDH1A1GAAHIF1AMAPTKDM4E
SCHEMBL7827157 0.74 AKR1B1 (0.67) AKR1B1TDP1GAAMAPTKDM4E
SCHEMBL11500783 0.74 KDM4E (0.51) AKR1B1TDP1MAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229910-A1 Therapeutic compounds N.V. ORGANON (NL) 2004-11-18 US disclosed
EP-0898566-B1 SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION AKZO NOBEL NV (NL) 2002-11-06 EP disclosed
US-20020037885-A1 Therapeutic compounds DIJCKS FREDERICUS ANTONIUS (NL) 2002-03-28 US disclosed
US-6313139-B1 ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS AKZO NOBEL N. V. (NL) 2001-11-06 US disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed
EP-0898566-A1 SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION Akzo Nobel N.V. (NL) 1999-03-03 EP disclosed
WO-1997040027-A1 SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION AKZO NOBEL N.V. (NL) 1997-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229910-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 ESR1 2865/4885ESR2 1589/4885FFAR4 1056/4885
US-20020037885-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 ESR1 2865/4885ESR2 1589/4885FFAR4 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.